Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Evaluating Perioperative Chemotherapy for Pancreatic Cancer
Clinical Breakthroughs

Evaluating Perioperative Chemotherapy for Pancreatic Cancer

By Melissa RohmanFeb 26, 2021
Share
Facebook Twitter Email
James Wade, III, MD, associate professor of Medicine in the Division of Hematology and Oncology, was a co-author of the clinical trial published in JAMA Oncology.

Perioperative chemotherapy did not improve overall survival for patients with resectable pancreatic cancer, according to a recent Northwestern Medicine clinical trial published in JAMA Oncology.

While better systemic treatments are still needed for patients, the preoperative approach used in the current trial may help guide future testing of other treatment strategies, according to James Wade, III, MD, associate professor of Medicine in the Division of Hematology and Oncology and a co-author of the study.

Over the last several decades the incidence of pancreatic cancer has increased, with more than 60,000 cases estimated to be diagnosed this year alone. While the overall long-term survival rate is less than 10 percent, that milestone is more likely if patients receive a pancreatectomy, the surgical removal of some or all of the pancreas. However, less than half of patients are candidates for this procedure, according to Wade.

In the current multi-institutional clinical trial, investigators enrolled patients between the ages of 18 and 75 years with localized pancreatic cancer who were eligible for a pancreatectomy. Patients were randomized to receive one of two chemotherapy regimens — fluorouracil, irinotecan and oxaliplatin, or gemcitabine/nab-paclitaxel— for 12 weeks before surgery and 12 weeks after surgery.

“The design was to ‘pick the winner’ of the two chemotherapy regimens for future clinical trial designs, with an overall two-year survival goal of 58 percent for each treatment group,” Wade said.

Of the total number of eligible participants, 46 percent completed all six cycles of chemotherapy. Overall survival at two years was 47 percent for the fluorouracil, irinotecan and oxaliplatin group, compared to 48 percent for the gemcitabine/nab-paclitaxel group.

Although the trial did not meet the two-year survival target of 58 percent, the trial suggests that either perioperative chemotherapy regimen can be delivered safely and does not interfere with planned surgery, according to the authors.

“Clearly better systemic treatments are needed for pancreatic cancer, but it is now known that the preoperative strategy used in this study can be a model for testing future regimens,” Wade said.

This work received support from the National Cancer Institute grants CA180888, CA180819, CA180820, CA180821, CA189830, CA180801, CA189953, CA189957, CA239767, CA189821, CA189972, CA233230, CA189858, CA189958, CA189822, CA189848, CA189971, CA13612, CA189873, CA189856, CA180798, CA189861 and CA189954.

Cancer Medicine Patient Care Research
Share. Facebook Twitter Email

Related Posts

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

Comments are closed.

Latest News

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM651
20230317_NM610
20230317_NM569
20230317_NM537
20230317_NM331
20230317_NM323
20230317_NM316
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.